Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women

J. S. Danik; J. E. Buring; D. I. Chasman; R. Y.L. Zee; P. M. Ridker; R. J. Glynn

doi:10.1111/jth.12056

Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women

J. S. Danik, J. E. Buring, D. I. Chasman, R. Y.L. Zee, P. M. Ridker, R. J. Glynn

Research output: Contribution to journal › Letter › peer-review

31 Scopus citations

Original language	English
Pages (from-to)	205-208
Number of pages	4
Journal	Journal of Thrombosis and Haemostasis
Volume	11
Issue number	1
DOIs	https://doi.org/10.1111/jth.12056
State	Published - Jan 2013
Externally published	Yes

Access to Document

10.1111/jth.12056

Cite this

@article{96c037c6c4f245f9b4d63c33183b38df,

title = "Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women",

author = "Danik, {J. S.} and Buring, {J. E.} and Chasman, {D. I.} and Zee, {R. Y.L.} and Ridker, {P. M.} and Glynn, {R. J.}",

note = "Funding Information: J. S. Danik has received support from the National Heart, Lung and Blood Institute (HL‐076443) and the American Heart Association (D005113). R. J. Glynn reports funding from NIH grant AG031061. J. E. Buring has received investigator‐initiated research funding and support as Principal Investigator from the National Institutes of Health (the National Heart, Lung, and Blood Institute, the National Cancer Institute, and the National Institute of Aging) and Dow Corning Corporation, research support for pills and/or packaging from Bayer Heath Care and the Natural Source Vitamin E Association, honoraria from Bayer for speaking engagements, and serves on an external scientific advisory committee for a study by Procter & Gamble. P. M. Ridker reports that he currently or in the past 5 years has received research funding support from not‐for‐profit entities including the National Heart, Lung, and Blood Institute, the National Cancer Institute, the American Heart Association, the Doris Duke Charitable Foundation, the Leducq Foundation, the Donald W Reynolds Foundation, and the James and Polly Annenberg La Vea Charitable Trusts. P. M. Ridker also reports that currently or in the past 5 years he has received investigator‐initiated research support from for‐profit entities including Astra‐Zeneca, Bayer, Bristol‐Myers Squibb, Dade‐Behring, Novartis, Pharmacia, Roche, Sanofi‐Aventis and Variagenics. P. M. Ridker reports being listed as a co‐inventor on patents held by the Brigham and Women{\textquoteright}s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and has served as a consultant to Schering‐Plough, Sanofi/Aventis, AstraZeneca, Isis Pharmaceutical, Dade‐Behring and Interleukin genetics. The funding agencies played no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, and preparation, review or approval of the manuscript. Funding Information: This work was supported by NIH grants AG031061, CA047988, HL043851, HL080467, HL099355 and HL007575, and by a grant from the Donald W. Reynolds Foundation (Las Vegas, NV). ",

year = "2013",

month = jan,

doi = "10.1111/jth.12056",

language = "English",

volume = "11",

pages = "205--208",

journal = "Journal of Thrombosis and Haemostasis",

issn = "1538-7933",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women

AU - Danik, J. S.

AU - Buring, J. E.

AU - Chasman, D. I.

AU - Zee, R. Y.L.

AU - Ridker, P. M.

AU - Glynn, R. J.

N1 - Funding Information: J. S. Danik has received support from the National Heart, Lung and Blood Institute (HL‐076443) and the American Heart Association (D005113). R. J. Glynn reports funding from NIH grant AG031061. J. E. Buring has received investigator‐initiated research funding and support as Principal Investigator from the National Institutes of Health (the National Heart, Lung, and Blood Institute, the National Cancer Institute, and the National Institute of Aging) and Dow Corning Corporation, research support for pills and/or packaging from Bayer Heath Care and the Natural Source Vitamin E Association, honoraria from Bayer for speaking engagements, and serves on an external scientific advisory committee for a study by Procter & Gamble. P. M. Ridker reports that he currently or in the past 5 years has received research funding support from not‐for‐profit entities including the National Heart, Lung, and Blood Institute, the National Cancer Institute, the American Heart Association, the Doris Duke Charitable Foundation, the Leducq Foundation, the Donald W Reynolds Foundation, and the James and Polly Annenberg La Vea Charitable Trusts. P. M. Ridker also reports that currently or in the past 5 years he has received investigator‐initiated research support from for‐profit entities including Astra‐Zeneca, Bayer, Bristol‐Myers Squibb, Dade‐Behring, Novartis, Pharmacia, Roche, Sanofi‐Aventis and Variagenics. P. M. Ridker reports being listed as a co‐inventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and has served as a consultant to Schering‐Plough, Sanofi/Aventis, AstraZeneca, Isis Pharmaceutical, Dade‐Behring and Interleukin genetics. The funding agencies played no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, and preparation, review or approval of the manuscript. Funding Information: This work was supported by NIH grants AG031061, CA047988, HL043851, HL080467, HL099355 and HL007575, and by a grant from the Donald W. Reynolds Foundation (Las Vegas, NV).

PY - 2013/1

Y1 - 2013/1

UR - http://www.scopus.com/inward/record.url?scp=84873044293&partnerID=8YFLogxK

U2 - 10.1111/jth.12056

DO - 10.1111/jth.12056

M3 - Letter

C2 - 23137279

AN - SCOPUS:84873044293

SN - 1538-7933

VL - 11

SP - 205

EP - 208

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

IS - 1

ER -